Zobrazeno 1 - 10
of 84
pro vyhledávání: '"J A Secrist"'
Autor:
Claire M. Patterson, Srividya B. Balachander, Iain Grant, Petar Pop-Damkov, Brian Kelly, William McCoull, Jeremy Parker, Michael Giannis, Kathryn J. Hill, Francis D. Gibbons, Edward J. Hennessy, Paul Kemmitt, Alexander R. Harmer, Sonya Gales, Stuart Purbrick, Sean Redmond, Matthew Skinner, Lorraine Graham, J. Paul Secrist, Alwin G. Schuller, Shenghua Wen, Ammar Adam, Corinne Reimer, Justin Cidado, Martin Wild, Eric Gangl, Stephen E. Fawell, Jamal Saeh, Barry R. Davies, David J. Owen, Marianne B. Ashford
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Claire Patterson et al. present the design and development of AZD0466, a drug-dendrimer conjugate, and use preclinical and mathematical models to determine the optimal release rate of the drug from the dendrimer carrier for maximal therapeutic index
Externí odkaz:
https://doaj.org/article/722de1f4d6464ec9a94bce51fe4fc356
Autor:
Ardeshir Goliaei, Haley A. Woods, Adriana E. Tron, Matthew A. Belmonte, J. Paul Secrist, Douglas Ferguson, Lisa Drew, Adrian J. Fretland, Bree B. Aldridge, Francis D. Gibbons
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 10, Pp 561-570 (2020)
Anticancer efficacy is driven not only by dose but also by frequency and duration of treatment. We describe a multiscale model combining cell cycle, cellular heterogeneity of B‐cell lymphoma 2 family proteins, and pharmacology of AZD5991, a potent
Externí odkaz:
https://doaj.org/article/07ad18bfe7b84642b234c602cec0a6fa
Autor:
Joan Montero, Cécile Gstalder, Daniel J. Kim, Dorota Sadowicz, Wayne Miles, Michael Manos, Justin R. Cidado, J. Paul Secrist, Adriana E. Tron, Keith Flaherty, F. Stephen Hodi, Charles H. Yoon, Anthony Letai, David E. Fisher, Rizwan Haq
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
MAPK-targeted therapies fail to achieve complete remission. Here, the authors show that anti-apoptosis resistance is acquired in these targeted therapies through the mRNA destabilization of NOXA which leads to dependence on MCL-1, and that sequential
Externí odkaz:
https://doaj.org/article/f51e8b007adc48feb4f6169ad611de36
Autor:
Adriana E. Tron, Matthew A. Belmonte, Ammar Adam, Brian M. Aquila, Lawrence H. Boise, Elisabetta Chiarparin, Justin Cidado, Kevin J. Embrey, Eric Gangl, Francis D. Gibbons, Gareth P. Gregory, David Hargreaves, J. Adam Hendricks, Jeffrey W. Johannes, Ricky W. Johnstone, Steven L. Kazmirski, Jason G. Kettle, Michelle L. Lamb, Shannon M. Matulis, Ajay K. Nooka, Martin J. Packer, Bo Peng, Philip B. Rawlins, Daniel W. Robbins, Alwin G. Schuller, Nancy Su, Wenzhan Yang, Qing Ye, Xiaolan Zheng, J. Paul Secrist, Edwin A. Clark, David M. Wilson, Stephen E. Fawell, Alexander W. Hird
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
High expression of Mcl-1 promotes tumorigenesis and resistance to anticancer therapies. Here they report a macrocyclic molecule with high selectivity and affinity for Mcl-1 that exhibits potent anti-tumor effects as single agent and in combination wi
Externí odkaz:
https://doaj.org/article/814ff3ef6b204d84917e2b025f3e1da9
Autor:
Ricky W. Johnstone, Saverio Minucci, J. Paul Secrist, Victoria M. Richon, Joey L. Methot, Thomas A. Miller, Nicole D. Ozerova, Astrid M. Kral, Susanna Chiocca, Claudia Miccolo, Ross A. Dickins, Ailsa J. Christiansen, Jessica E. Bolden, Carleen Cullinane, Kellie-Marie Banks, Christopher J.P. Clarke, Leonie A. Cluse, Michael Bots, Geoffrey M. Matthews, Andrea Newbold
PDF file - 1496K, Supplementary Methods; Supplementary Figure 1: Production and characterisation of tumor cells dependent on Bcr-Abl for survival; Supplementary Figure 2: HDACi with different isoform specificities induce apoptosis of Bcr-Abl(p210) ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51845ee47377f86143df810793c178b8
https://doi.org/10.1158/1535-7163.22498807.v1
https://doi.org/10.1158/1535-7163.22498807.v1
Autor:
Ricky W. Johnstone, Saverio Minucci, J. Paul Secrist, Victoria M. Richon, Joey L. Methot, Thomas A. Miller, Nicole D. Ozerova, Astrid M. Kral, Susanna Chiocca, Claudia Miccolo, Ross A. Dickins, Ailsa J. Christiansen, Jessica E. Bolden, Carleen Cullinane, Kellie-Marie Banks, Christopher J.P. Clarke, Leonie A. Cluse, Michael Bots, Geoffrey M. Matthews, Andrea Newbold
Histone deacetylase inhibitors (HDACi) are anticancer agents that induce hyperacetylation of histones, resulting in chromatin remodeling and transcriptional changes. In addition, nonhistone proteins, such as the chaperone protein Hsp90, are functiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::367cd916bfc9f81672a5130168011dac
https://doi.org/10.1158/1535-7163.c.6535972.v1
https://doi.org/10.1158/1535-7163.c.6535972.v1
Autor:
Francis D. Gibbons, Stephen E. Fawell, Barry R. Davies, J. Paul Secrist, Michael Zinda, Martin Wild, Eric Gangl, Ricky W. Johnstone, Andrea Newbold, Gareth P. Gregory, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Alwin Schuller, Nancy Su, Omid Tavana, Areya Tabatabai, Jamal C. Saeh, William McCoull, Edward J. Hennessy, Stephanos Ioannidis, Thomas Gero, R. Bruce Diebold, Jeffrey Varnes, Shannon K. McWeeney, Stephen E. Kurtz, Jeffrey W. Tyner, Tristan Lubinski, Kathleen Burke, Deborah Lawson, Shenghua Wen, Terry Macintyre, Paula Lewis, Ammar Adam, Justin Cidado, Kate F. Byth, Steven W. Criscione, Srividya B. Balachander
Figure S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::444106ead769434517a6030981d594b4
https://doi.org/10.1158/1078-0432.22476393.v1
https://doi.org/10.1158/1078-0432.22476393.v1
Autor:
Francis D. Gibbons, Stephen E. Fawell, Barry R. Davies, J. Paul Secrist, Michael Zinda, Martin Wild, Eric Gangl, Ricky W. Johnstone, Andrea Newbold, Gareth P. Gregory, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Alwin Schuller, Nancy Su, Omid Tavana, Areya Tabatabai, Jamal C. Saeh, William McCoull, Edward J. Hennessy, Stephanos Ioannidis, Thomas Gero, R. Bruce Diebold, Jeffrey Varnes, Shannon K. McWeeney, Stephen E. Kurtz, Jeffrey W. Tyner, Tristan Lubinski, Kathleen Burke, Deborah Lawson, Shenghua Wen, Terry Macintyre, Paula Lewis, Ammar Adam, Justin Cidado, Kate F. Byth, Steven W. Criscione, Srividya B. Balachander
contains methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f66d7cdc5a26035ed01be67bc7dad53
https://doi.org/10.1158/1078-0432.22476381.v1
https://doi.org/10.1158/1078-0432.22476381.v1
Autor:
Francis D. Gibbons, Stephen E. Fawell, Barry R. Davies, J. Paul Secrist, Michael Zinda, Martin Wild, Eric Gangl, Ricky W. Johnstone, Andrea Newbold, Gareth P. Gregory, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Alwin Schuller, Nancy Su, Omid Tavana, Areya Tabatabai, Jamal C. Saeh, William McCoull, Edward J. Hennessy, Stephanos Ioannidis, Thomas Gero, R. Bruce Diebold, Jeffrey Varnes, Shannon K. McWeeney, Stephen E. Kurtz, Jeffrey W. Tyner, Tristan Lubinski, Kathleen Burke, Deborah Lawson, Shenghua Wen, Terry Macintyre, Paula Lewis, Ammar Adam, Justin Cidado, Kate F. Byth, Steven W. Criscione, Srividya B. Balachander
Purpose:Targeting Bcl-2 family members upregulated in multiple cancers has emerged as an important area of cancer therapeutics. While venetoclax, a Bcl-2–selective inhibitor, has had success in the clinic, another family member, Bcl-xL, has also em
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8844690ddeffa8863fd595c34c80f01
https://doi.org/10.1158/1078-0432.c.6529392
https://doi.org/10.1158/1078-0432.c.6529392
Autor:
Shenghua Wen, Srividya B. Balachander, Francis D. Gibbons, Michael Zinda, William McCoull, Nancy Su, Barry R. Davies, Stephen E. Kurtz, Terry MacIntyre, Edward J. Hennessy, Martin Wild, Paula Lewis, Ricky W. Johnstone, Jamal Carlos Saeh, Kathleen A. Burke, Omid Tavana, Andrea Newbold, Elizabeth A. Coker, Alwin Schuller, Justin Cidado, Diebold R Bruce, Tristan J. Lubinski, Steven Criscione, J. Paul Secrist, Kate Byth, Gareth P. Gregory, Deborah Lawson, Ammar Adam, Shannon K. McWeeney, Stephen Fawell, Thomas Gero, Jeffrey G. Varnes, Eric Gangl, Patricia Jaaks, Jeffrey W. Tyner, Mathew J. Garnett, Areya Tabatabai, Stephanos Ioannidis
Publikováno v:
Clinical Cancer Research. 26:6535-6549
Purpose: Targeting Bcl-2 family members upregulated in multiple cancers has emerged as an important area of cancer therapeutics. While venetoclax, a Bcl-2–selective inhibitor, has had success in the clinic, another family member, Bcl-xL, has also e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::564420d79c6feacf9af617f03b6937bc
https://doi.org/10.1158/1078-0432.ccr-20-0863
https://doi.org/10.1158/1078-0432.ccr-20-0863